177 related articles for article (PubMed ID: 15944449)
1. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136.
Clingen PH; De Silva IU; McHugh PJ; Ghadessy FJ; Tilby MJ; Thurston DE; Hartley JA
Nucleic Acids Res; 2005; 33(10):3283-91. PubMed ID: 15944449
[TBL] [Abstract][Full Text] [Related]
2. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells.
De Silva IU; McHugh PJ; Clingen PH; Hartley JA
Mol Cell Biol; 2000 Nov; 20(21):7980-90. PubMed ID: 11027268
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
[TBL] [Abstract][Full Text] [Related]
4. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
De Silva IU; McHugh PJ; Clingen PH; Hartley JA
Nucleic Acids Res; 2002 Sep; 30(17):3848-56. PubMed ID: 12202770
[TBL] [Abstract][Full Text] [Related]
5. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
6. Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies.
Martin C; Ellis T; McGurk CJ; Jenkins TC; Hartley JA; Waring MJ; Thurston DE
Biochemistry; 2005 Mar; 44(11):4135-47. PubMed ID: 15766241
[TBL] [Abstract][Full Text] [Related]
7. Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.
Wilkinson GP; Taylor JP; Shnyder S; Cooper P; Howard PW; Thurston DE; Jenkins TC; Loadman PM
Invest New Drugs; 2004 Aug; 22(3):231-40. PubMed ID: 15122070
[TBL] [Abstract][Full Text] [Related]
8. Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers.
Rahman KM; James CH; Thurston DE
Nucleic Acids Res; 2011 Jul; 39(13):5800-12. PubMed ID: 21427082
[TBL] [Abstract][Full Text] [Related]
9. Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis.
Enoiu M; Jiricny J; Schärer OD
Nucleic Acids Res; 2012 Oct; 40(18):8953-64. PubMed ID: 22810206
[TBL] [Abstract][Full Text] [Related]
10. Double-strand breaks induce homologous recombinational repair of interstrand cross-links via cooperation of MSH2, ERCC1-XPF, REV3, and the Fanconi anemia pathway.
Zhang N; Liu X; Li L; Legerski R
DNA Repair (Amst); 2007 Nov; 6(11):1670-8. PubMed ID: 17669695
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents.
Damia G; Imperatori L; Stefanini M; D'Incalci M
Int J Cancer; 1996 Jun; 66(6):779-83. PubMed ID: 8647649
[TBL] [Abstract][Full Text] [Related]
12. Interstrand cross-links induce DNA synthesis in damaged and undamaged plasmids in mammalian cell extracts.
Li L; Peterson CA; Lu X; Wei P; Legerski RJ
Mol Cell Biol; 1999 Aug; 19(8):5619-30. PubMed ID: 10409751
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.
Gregson SJ; Howard PW; Hartley JA; Brooks NA; Adams LJ; Jenkins TC; Kelland LR; Thurston DE
J Med Chem; 2001 Mar; 44(5):737-48. PubMed ID: 11262084
[TBL] [Abstract][Full Text] [Related]
14. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.
Gu Y; Patterson AV; Atwell GJ; Chernikova SB; Brown JM; Thompson LH; Wilson WR
Mol Cancer Ther; 2009 Jun; 8(6):1714-23. PubMed ID: 19509245
[TBL] [Abstract][Full Text] [Related]
15. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2, 1-c][1,4]benzodiazepine system.
Wilson SC; Howard PW; Forrow SM; Hartley JA; Adams LJ; Jenkins TC; Kelland LR; Thurston DE
J Med Chem; 1999 Oct; 42(20):4028-41. PubMed ID: 10514273
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.
Usanova S; Piée-Staffa A; Sied U; Thomale J; Schneider A; Kaina B; Köberle B
Mol Cancer; 2010 Sep; 9():248. PubMed ID: 20846399
[TBL] [Abstract][Full Text] [Related]
19. Differential processing of UV mimetic and interstrand crosslink damage by XPF cell extracts.
Zhang N; Zhang X; Peterson C; Li L; Legerski R
Nucleic Acids Res; 2000 Dec; 28(23):4800-4. PubMed ID: 11095693
[TBL] [Abstract][Full Text] [Related]
20. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
